| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer
|
Pentheroudakis, George
|
|
2018
|
17 |
4 |
p. e631-e637
|
article
|
| 2 |
Association of Clinicopathologic and Molecular Markers on Stage-specific Survival of Right Versus Left Colon Cancer
|
Narayanan, Sumana
|
|
2018
|
17 |
4 |
p. e671-e678
|
article
|
| 3 |
Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer
|
Sundar, Raghav
|
|
2018
|
17 |
4 |
p. 280-284
|
article
|
| 4 |
ATM Is Required for the Repair of Oxaliplatin-Induced DNA Damage in Colorectal Cancer
|
Bakkenist, Christopher J.
|
|
2018
|
17 |
4 |
p. 255-257
|
article
|
| 5 |
BRCA Mutation and Its Association With Colorectal Cancer
|
Soyano, Aixa E.
|
|
2018
|
17 |
4 |
p. e647-e650
|
article
|
| 6 |
Capecitabine Plus Oxaliplatin and Bevacizumab, Followed by Maintenance Treatment With Capecitabine and Bevacizumab for Patients Aged > 75 Years With Metastatic Colorectal Cancer
|
Petrioli, Roberto
|
|
2018
|
17 |
4 |
p. e663-e669
|
article
|
| 7 |
Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study
|
Shapiro, Jeremy D.
|
|
2018
|
17 |
4 |
p. 313-319
|
article
|
| 8 |
Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States
|
Cho, Sang Kyu
|
|
2018
|
17 |
4 |
p. e751-e761
|
article
|
| 9 |
Disease Characteristics, Clinical Management, and Outcomes of Young Patients With Colon Cancer: A Population-based Study
|
Rodriguez, Laura
|
|
2018
|
17 |
4 |
p. e651-e661
|
article
|
| 10 |
Editorial Board
|
|
|
2018
|
17 |
4 |
p. A1
|
article
|
| 11 |
Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies
|
Gibbs, Peter
|
|
2018
|
17 |
4 |
p. e617-e629
|
article
|
| 12 |
Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy
|
Petrioli, Roberto
|
|
2018
|
17 |
4 |
p. 307-312
|
article
|
| 13 |
Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer
|
Sunakawa, Yu
|
|
2018
|
17 |
4 |
p. e741-e749
|
article
|
| 14 |
Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial
|
Noepel-Duennebacke, Stefanie
|
|
2018
|
17 |
4 |
p. e733-e739
|
article
|
| 15 |
Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib
|
Unseld, Matthias
|
|
2018
|
17 |
4 |
p. 274-279
|
article
|
| 16 |
Perioperative Management for Colorectal Peritoneal Metastases
|
Kim, Bradford J.
|
|
2018
|
17 |
4 |
p. 249-250
|
article
|
| 17 |
Perioperative Systemic Chemotherapy, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: Results of the Prospective Multicenter Phase 2 COMBATAC Trial
|
Glockzin, Gabriel
|
|
2018
|
17 |
4 |
p. 285-296
|
article
|
| 18 |
Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics
|
Khan, Maliha
|
|
2018
|
17 |
4 |
p. e699-e709
|
article
|
| 19 |
Prognostic Value of the Microsatellite Instability Status in Patients With Stage II/III Rectal Cancer Following Upfront Surgery
|
Oh, Chung Ryul
|
|
2018
|
17 |
4 |
p. e679-e685
|
article
|
| 20 |
Recent Advances in the Clinical Development of Immune Checkpoint Blockade Therapy for Mismatch Repair Proficient (pMMR)/non-MSI-H Metastatic Colorectal Cancer
|
Lee, James J.
|
|
2018
|
17 |
4 |
p. 258-273
|
article
|
| 21 |
Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials
|
Yoshino, Takayuki
|
|
2018
|
17 |
4 |
p. e719-e732
|
article
|
| 22 |
Risk Factors and Adequate Management for Complications of Bevacizumab Treatment Requiring Surgical Intervention in Patients With Metastatic Colorectal Cancer
|
Bong, Jun Woo
|
|
2018
|
17 |
4 |
p. e639-e645
|
article
|
| 23 |
Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer
|
Tsuchihashi, Kenji
|
|
2018
|
17 |
4 |
p. e687-e697
|
article
|
| 24 |
Selection of Second-line Anti-angiogenic Agents After Failure of Bevacizumab-containing First-line Chemotherapy in Metastatic Colorectal Cancer
|
Boku, Narikazu
|
|
2018
|
17 |
4 |
p. 251-254
|
article
|
| 25 |
Sex Disparities in Outcomes of Early Stage Colorectal Cancer: A Population-Based Study
|
Samawi, Haider H.
|
|
2018
|
17 |
4 |
p. e711-e717
|
article
|
| 26 |
Short-Course Radiotherapy in Neoadjuvant Treatment for Rectal Cancer: A Systematic Review and Meta-analysis
|
Ma, Bin
|
|
2018
|
17 |
4 |
p. 320-330.e5
|
article
|
| 27 |
Short-course Versus Long-course Neoadjuvant Therapy for Non-metastatic Rectal Cancer: Patterns of Care and Outcomes From the National Cancer Database
|
Dutta, Sunil W.
|
|
2018
|
17 |
4 |
p. 297-306
|
article
|
| 28 |
Table of Contents
|
|
|
2018
|
17 |
4 |
p. A3-A7
|
article
|
Journal description